Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03734536
Other study ID # REGEN.PUB.2018.09
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date December 3, 2018
Est. completion date September 11, 2023

Study information

Verified date October 2023
Source Smith & Nephew, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Demonstrate that REGENETEN is superior to standard repair techniques when surgically treating high-grade (>50%) partial-thickness tears because REGENETEN preserves more of the native tendon footprint resulting in less postoperative pain and faster recovery.


Description:

The objective of this study is to demonstrate arthroscopic surgical treatment of high-grade (>50%) partial-thickness tears using REGENETEN yields statistically superior patient post-operative recovery outcomes, faster return to activities of daily living, and less health care utilization versus standard surgical repair techniques.


Recruitment information / eligibility

Status Terminated
Enrollment 118
Est. completion date September 11, 2023
Est. primary completion date September 11, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients will be considered qualified for enrollment if they meet the following criteria: 1. Male or female =18 years 2. High-grade (>50% tendon thickness) partial-thickness tear 3. Failed conservative medical management of the tendon tear defined as: 1. Four (4) to six (6) weeks of formal physical therapy or guided home exercises 2. Activity modification 3. Shoulder injection at the discretion of the surgeon 4. Able to comply with the post-operative physiotherapy and follow-up schedule 5. Able to speak and read English Provide written informed consent Exclusion Criteria: Any one (1) of the following criteria will disqualify a patient from participation in the study: 1. Prior shoulder surgery on index shoulder within 12 months of enrollment 2. Failed primary rotator cuff surgery of the index shoulder 3. On steroids within 1 month of enrollment 4. Metastatic disease 5. Concomitant surgeries for bone defects requiring bone implantation (Latarjet procedures) or for superior labral tear from anterior to posterior (SLAP) 6. Concomitant biceps tenodesis 7. Rheumatoid arthritis 8. Advanced osteoarthritis 9. Fatty infiltration of the index shoulder rotator cuff muscle = Grade 3 10. Chronic pain disorders (i.e., fibromyalgia) 11. History of insulin dependent diabetes 12. History of heavy smoking (> 1 pack per day) within 6 months of enrollment 13. Currently involved in any injury litigation or workers compensation claims 14. Hypersensitivity to bovine-derived materials Medical or physical condition that, in the opinion of the Investigator, would preclude safe participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
REGENETEN™ Bioinductive Implant
The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
Arthroscopic repair of the high-grade (>50%) partialthickness
Surgical treatment of partial-thickness rotator cuff tears using standard techniques.

Locations

Country Name City State
United States Anne Arundel Medical Center/Luminis Health Annapolis Maryland
United States Texas Orthopedic Specialists Bedford Texas
United States Orthopedic Associates of SW Ohio Centerville Ohio
United States Syracuse Orthopedic Specialist DeWitt New York
United States University of Florida Orthopaedics and Sports Medicine Gainesville Florida
United States Baptist Health Jacksonville Beach Florida
United States University of Kentucky Lexington Kentucky
United States Ochsner Health Center New Orleans Louisiana
United States Columbia University New York New York
United States Harbin Clinic Rome Georgia

Sponsors (3)

Lead Sponsor Collaborator
Smith & Nephew, Inc. Global Research Solutions, Medical Metrics Diagnostics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary ASES (American Shoulder and Elbow Surgeons) score tear using standard surgical techniques. at 3 months following index surgery
Secondary ASES score over initial 3 months following index surgery
Secondary Single Assessment Numeric Value (SANE) score over initial 3 months following index surgery
Secondary ASES Visual Analog Scale (VAS) pain score over initial 3 months following index surgery
Secondary ASES score at 6, 12, 18 and 24 months following index surgery
Secondary SANE score at 6, 12, 18 and 24 months following index surgery
Secondary ASES VAS pain score at 6, 12, 18 and 24 months following index surgery
Secondary Shoulder Stiffness Visual Analog Scale (VAS) score Stiffness in the participant's index shoulder will be assessed using the shoulder stiffness VAS. The VAS is a continuous scale comprised of a horizontal line 100 millimeters (mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme: No Stiffness (0 mm) and Extreme Stiffness (100 mm). The VAS stiffness rating will be recorded pre-operatively, weekly from 1 week to 3 months post-surgery, and at 6 and 12 months post-surgery. over 12 months following index surgery
Secondary Cumulative opioid use to treat the index shoulder over 12 months following index surgery
Secondary Cumulative non-opioid prescription medication use to treat the index shoulder over 12 months following index surgery
Secondary Duration of shoulder immobilization following index surgery
Secondary Time to return to activities of daily living (ADLs) o Return to work by work type (sedentary; laborer) o Return to driving o Return to sports following index surgery
Secondary Incidence of progression to full-thickness tear within 12 months following index surgery
Secondary Incidence of progression to full-thickness tear within 24 months following index surgery
Secondary Incidence of revision surgery (index shoulder; all causes) within 24 months following index surgery
Secondary Aggregate health care utilization costs over 12 months following index surgery
Secondary Operating room time (index surgery) Intra-operative
Secondary Number of steroid injections over 12 months following index surgery
Secondary Number of unscheduled clinic visits over 12 months following index surgery
Secondary Number of for-cause imaging procedures over 12 months following index surgery